VDyne Appoints Mike Buck as Chairman and CEO to Lead Next Phase of its TTVR Program

MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDyne Inc. (“VDyne”), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of Mike Buck as Chairman and Chief Executive Officer.

Mr. Buck brings more than 30 years of leadership experience in cardiovascular medical technology. Most recently, he served as Chief Executive Officer of Verge Medical and previously was Founder and Chief Executive Officer of TRUVIC Medical (acquired by Imperative Care). Earlier in his career, he served as President of Cardinal Health’s Medical Products Division and held senior leadership roles at Abbott, including Corporate Vice President and global commercial leader for Abbott’s Vascular business, as well as leading Abbott’s global Licensing and Acquisitions function.

VDyne has conducted clinical studies across 15 countries, with more than 100 successful TTVR procedures to date. The Company has received FDA Breakthrough Device designation and is advancing toward CE Mark and initiation of its U.S. pivotal clinical study, positioning VDyne among companies advancing next-generation TTVR therapies.

“VDyne has built a strong clinical foundation, and the opportunity to improve the lives of patients with tricuspid regurgitation is significant. I look forward to working alongside this team as we advance the technology and continue building the clinical evidence behind it,” said Mike Buck.

“Mike brings deep experience in structural heart and a proven ability to build and lead strong teams. As VDyne advances its clinical programs, his leadership will be critical in guiding the company through its next phase,” said Dr. Greg Pearl, VDyne Board Member.

About VDyne Inc.

VDyne Inc. is a privately held medical device company based in Maple Grove, Minnesota, developing a transcatheter tricuspid valve replacement (TTVR) system for the treatment of tricuspid regurgitation.

VDyne’s TTVR system is currently under clinical investigation and is not approved for commercial sale in the United States or any other jurisdiction.

For more information, please visit www.vdyne.com